晚期乳腺癌β-tubulinⅢ和survivin的表达及与多西紫杉醇化疗疗效相关性分析

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (6): 666-671.

晚期乳腺癌β-tubulinⅢ和survivin的表达及与多西紫杉醇化疗疗效相关性分析

原少斐, 朱林佳, 郑维锷, 陈文俊, 陈华, 张武

温州医学院附属第三医院肿瘤中心,温州 325200,浙江

收稿日期:2011-05-17 修回日期:2011-05-30 发布日期:2011-07-25
通讯作者: 郑维锷,男,副主任医师,副教授,从事肿瘤内科治疗。 E-mail: zhengweie@sohu.com
作者简介:原少斐,男,硕士,医师,从事肿瘤内科治疗工作。 E-mail: ysf1004@163.com
基金资助:
温州市科技计划项目(Y20100024)

Analysis of the relationship between expression of β-tubulinⅢ, survivin and response to docetaxel in metastatic breast cancer

YUAN Shao-fei, ZHU Lin-jia, ZHENG Wei-e, CHEN Wen-jun, CHEN Hua, ZHANG Wu

Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College, Wenzhou 325000, Zhejiang, China

Received:2011-05-17 Revised:2011-05-30 Published:2011-07-25

摘要/Abstract

摘要： 目的: 探讨晚期乳腺癌中β-tubulinⅢ和survivin的表达与多西紫杉醇化疗疗效的关系。方法: 回顾性分析84例接受多西紫杉醇化疗的晚期乳腺癌患者的临床病理资料。免疫组织化学法检测肿瘤标本β-tubulinⅢ和survivin蛋白的表达,并对疗效、不良反应进行分析。结果: β-tubulinⅢ阳性表达率为 38.1％(32/84),survivin阳性表达率为 76.2％(64/84)。化疗有效率(CR+PR)为 52.38％,β-tubulinⅢ(+)的患者有效率低(37.50％),β-tubulinⅢ(-)患者有效率高(61.54％),差异有统计学意义(P<0.05)。survivin (+)组的有效率为 48.40％,低于survivin (-)组的 65.00％,差异有统计学意义P<0.05)。联合检测显示:β-tubulinⅢ(+)且survivin (+)组有效率为 25.0％,中位疾病无进展期为 3.9 个月,1年、2年生存率分别为 34.5%、15.1%,β-tubulinⅢ(-)且survivin (-)组有效率为 73.91％,中位疾病无进展期为 7.7 个月,1年、2年生存率分别为 61.6%、31.4%,差异均有统计学意义(P<0.05)。最常见的不良反应为骨髓抑制、消化道反应和脱发。结论: 联合检测β-tubulinⅢ和survivin的表达可作为多西紫杉醇化疗方案治疗转移性乳腺癌的疗效预测指标之一。

关键词: 晚期乳腺癌, 多西紫杉醇, β-微管蛋白Ⅲ, Survivin

Abstract: AIM: To investigate the expression of β-tubulinⅢ, survivin protein and chemoresistance to docetaxel in advanced gastric cancer. METHODS: Seventy-four patients of advanced gastric cancer treated with docetaxel were enrolled in this study and their tumor samples were collected retrospectively for analysis. The expression of β-tubulinⅢ, survivin protein in tumor samples was detected by the immuno- histochemical methods. The data of therapeutical effect and toxicity were collected and analyzed. RESULTS: β-tubulinⅢ positive staining accounted for 38.1％(32/84). Survivin positive staining accounted for 76.2％(64/84). There was no correlation between β-tubulinⅢ, survivin positive expression and age, gender, pathological type. The response rate(CR+PR)was 52.38％. Patients with overexpression β-tubulinⅢ were less response rate (37.50％vs 61.54％) to docetaxel (P<0.05). Patients with overexpression survivin were less response rate (48.40％vs 65.50％) to docetaxel (P<0.05). Patients with overexpression β-tubulinⅢ and survivin were also lower response rate (25.0％vs 73.91％, P<0.05). Patients with over expression β-tubulinⅢ and survivin have also lower the median time to progress and 1- and 2-year survival rates (3.9m vs 7.7m, 34.5% vs 61.6%, 15.1% vs 31.4%, P<0.05). The main side-effects were myelosuppression and digestive apparatus toxicity. CONCLUSION: The expression of β-tubulinⅢ and survivin is associated with clinical response to docetaxel chemotherapy in metastatic breast cancer and can be used as method of detection of sensitivity.

Key words: Metastatic breast cancer, Docetaxel, β-tubulinⅢ, Survivin

中图分类号:

R735.2

原少斐, 朱林佳, 郑维锷, 陈文俊, 陈华, 张武. 晚期乳腺癌β-tubulinⅢ和survivin的表达及与多西紫杉醇化疗疗效相关性分析[J]. 中国临床药理学与治疗学, 2011, 16(6): 666-671.

YUAN Shao-fei, ZHU Lin-jia, ZHENG Wei-e, CHEN Wen-jun, CHEN Hua, ZHANG Wu. Analysis of the relationship between expression of β-tubulinⅢ, survivin and response to docetaxel in metastatic breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 666-671.

参考文献

[1] Biganzoli L, Minisini A, Aapro M, et al. Chemotherapy for metastatic breast cancer[J]. Curr Opin Obstet Gynecol, 2004, 16(7):37-41.
[2] Jones SE, Erban J, Ovemoyer B, et al. Randomized phase Ⅲ study of docetaxel compared with paclitaxel in metastatic breast cancer[J]. Clin Oncol, 2005, 23(11):5542-5551.
[3] Grisko T, Williams A, Turkson J, et al. Persistent activation of state signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells[J]. Clin Cancer Res, 2006, 12(6):11-19.
[4] Banerjee A. Increased levels of tyrosinated alpha-beta (III)-and beta(IV)-tubulin isotypes in paclitaxel- resistant MCF-7 breast cancer cells[J]. Biochem Biophys Res Commun, 2002, 293(21):598-601.
[5] 王增, 翁琳, 程斌. 唑来磷酸防治芳香化酶抑制剂相关骨丢失临床研究进展[J]. 中国临床药理学与治疗学, 2010, 15(4):30-32.
[6] Bi6anzoli L, Minisini A, Aapro M, et al. Chemotherapy for metastatic breast cancer[J]. Curr Opin Obstet Gynecol, 2004, 16(9):37-41.
[7] Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer[J]. J Urol, 2003, 170(12):1709-1716.
[8] Campone M, Blasinska-Morawiec M, Tekiela A, et al. Phase II study of vinorelbine (altemating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer[J]. Cancer Chemother Pharmacol, 2009, 63(18):937-943.
[9] Kappler M, Rot S, Taubert H, et al. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions[J]. Cancer Gene Ther, 2007, 14(5): 994-1001.
[10] Altieri DC. Validating survivin as a cancer therapeutic target[J]. Nat Rev Cancer, 2003, 3(8):46-54.
[11] 王文武, 欧阳学农, 张霞. Survivin与bcl-2基因反义寡核酸联合对人乳腺癌裸鼠皮下移植瘤的治疗作用[J]. 中国临床药理学与治疗学, 2006, 11(9):1164-1167.
[12] Ranganathan S, Benetatos CA, Colarusso PJ, et al. Altered-tubulin isotype expression in paclitaxel resistant human prostate carcinoma cells[J]. Br J Cancer, 2008, 77(4):562-566.

[1]	朱晓婕，孔颖，刘琦，卢杨，赵娣，李宁，陈西敬. 叶酸靶向多西紫杉醇纳米肺吸入粉雾剂的制备及评价[J]. 中国临床药理学与治疗学, 2017, 22(5): 495-500.
[2]	钟芳芳，吴承龙，孙新芳，王赵伟. 补阳还五汤联合依达拉奉对脑缺血后细胞凋亡及survivin和caspase-3表达的影响[J]. 中国临床药理学与治疗学, 2016, 21(10): 1103-1107.
[3]	袁宏钧. 靶向药物曲妥珠单抗联合化疗对人类表皮生长因子受体2阳性局部晚期乳腺癌患者临床疗效研究[J]. 中国临床药理学与治疗学, 2015, 20(1): 86-90.
[4]	李招发, 王从阳, 邓小英, 惠二京. 融合受体eDR4/iFas提高sTRAIL对HT-29细胞凋亡的敏感性[J]. 中国临床药理学与治疗学, 2014, 19(9): 966-972.
[5]	储冀汝, 谢海棠, 李娟, 钟正灵. Survivin蛋白在抗肿瘤治疗中的研究进展[J]. 中国临床药理学与治疗学, 2014, 19(7): 835-840.
[6]	林素芳. 多西紫杉醇对人鼻咽癌CNE-2细胞辐射敏感性及侵袭转移相关因子表达的影响[J]. 中国临床药理学与治疗学, 2014, 19(6): 620-625.
[7]	沈杰, 储冀汝, 贾元威, 刘晓平. 干扰survivin表达减少肿瘤细胞对紫外线诱导DNA损伤的修复作用[J]. 中国临床药理学与治疗学, 2014, 19(5): 497-502.
[8]	赵文英, 吴万春. 心理危机干预改善晚期乳腺癌患者生活质量的研究[J]. 中国临床药理学与治疗学, 2010, 15(1): 101-105.
[9]	赵令武, 万福生. 白英水提物诱导人宫颈癌HeLa细胞凋亡的实验研究[J]. 中国临床药理学与治疗学, 2007, 12(8): 883-887.
[10]	陈颇静, 蔡志春, 黎敏, 李健哲, 王晨静, 吴建华, 方云祥. 氟伐他汀对溶血性磷脂酰胆碱致动脉平滑肌细胞增殖和凋亡相关因子表达的影响[J]. 中国临床药理学与治疗学, 2007, 12(6): 649-654.
[11]	黄鹤, 吴佩, 洪书剑, 茆家定, 芮景. 胰腺癌Bx-PC3细胞Survivin基因ShRNA质粒表达载体的构建[J]. 中国临床药理学与治疗学, 2006, 11(6): 655-658.
[12]	王文武, 欧阳学农, 张霞, 姜浩. Survivin 与bcl-2 基因反义寡核酸联合对人乳腺癌裸鼠皮下移植瘤的治疗作用[J]. 中国临床药理学与治疗学, 2006, 11(10): 1164-1167.
[13]	彭磊, 王臻, 王庆良, 曹云新, 朱德生, 张志培, 吴银松, 施新猷. 多西紫杉醇体外诱导骨肉瘤细胞系 pl-1 的凋亡¹[J]. 中国临床药理学与治疗学, 2002, 7(1): 1-4.